Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Phase 2CompletedNCT00237172

Novartis Pharmaceuticals72 enrolled

Overview

This is a extension study of CSTI571B1201 study

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastrointestinal Stromal Tumors

Interventions

Imatinib MesylateDRUG

once daily

Eligibility

Sex: ALLMin age: 20 YearsMax age: 74 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Patients who completed the CSTI571B1201 study Exclusion Criteria: \- Other protocol-defined inclusion / exclusion criteria may apply.

Outcomes

Primary Outcomes

To study the antineoplastic effect of the investigational drug.

Secondary Outcomes

To study the safety and pharmacokinetics of the investigational drug.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.